Dana E Rollison
Overview
Explore the profile of Dana E Rollison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zitu M, Le T, Duong T, Haddadan S, Garcia M, Amorrortu R, et al.
BJR Artif Intell
. 2025 Jan;
2(1):ubae019.
PMID: 39777117
This review examines the use of large language models (LLMs) in cancer, analysing articles sourced from PubMed, Embase, and Ovid Medline, published between 2017 and 2024. Our search strategy included...
2.
Kansara B, Basta A, Mikhael M, Perkins R, Reisman P, Hallanger-Johnson J, et al.
Appl Clin Inform
. 2024 May;
15(2):404-413.
PMID: 38777326
Objectives: There is limited research on suicide risk screening (SRS) among head and neck cancer (HNC) patients, a population at increased risk for suicide. To address this gap, this single-site...
3.
Zhao Y, Amorrortu R, Stewart S, Ghia K, Williams V, Sondak V, et al.
BMC Cancer
. 2023 Nov;
23(1):1084.
PMID: 37946198
Background: Survival following melanoma and chronic lymphocytic leukemia (CLL) have both been individually associated with previous history of non-melanoma skin cancers (specifically keratinocyte carcinomas [KC]). Furthermore, melanoma and CLL have...
4.
Amorrortu R, Zhao Y, Keenan R, Gilbert S, Rollison D
J Racial Ethn Health Disparities
. 2023 Nov;
12(1):107-117.
PMID: 37917235
Background: COVID-19 infection severity differs by race and ethnicity, but its long-term effect on cancer-related outcomes is unknown. Therefore, information on COVID-19 history is critical to ascertain among new cancer...
5.
Amorrortu R, Garcia M, Zhao Y, El Naqa I, Balagurunathan Y, Chen D, et al.
JNCI Cancer Spectr
. 2023 Sep;
7(6).
PMID: 37738580
Background: Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Criteria in Solid Tumors. However, novel, scalable approaches to estimate disease progression...
6.
Rollison D, Gonzalez B, Turner K, Jim H, Zhao Y, Amorrortu R, et al.
Cancer Med
. 2023 Aug;
12(18):19033-19046.
PMID: 37596773
Background: Patient-reported data can improve quality of healthcare delivery and patient outcomes. Moffitt Cancer Center ("Moffitt") administers the Electronic Patient Questionnaire (EPQ) to collect data on demographics, including sexual orientation...
7.
Gorak E, Otterstatter M, Baghdadi T, Gillis N, Foran J, Liu J, et al.
Blood Adv
. 2023 Aug;
7(20):6120-6129.
PMID: 37552083
Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying...
8.
Rollison D, M Levin G, Warner J, Pinder R, Havener L, Behera M, et al.
J Registry Manag
. 2023 Jun;
49(4):153-160.
PMID: 37260815
Cancer surveillance at the population level is a highly labor-intensive process, with certified tumor registrars (CTRs) manually reviewing medical charts of cancer patients and entering information into local databases that...
9.
Patel K, Tabriz A, Turner K, Gonzalez B, Oswald L, Jim H, et al.
J Natl Compr Canc Netw
. 2023 May;
21(5):496-502.e6.
PMID: 37156477
Background: Patients with cancer require timely access to care so that healthcare providers can prepare an optimal treatment plan with significant implications for quality of life and mortality. The COVID-19...
10.
Kirtane K, Zhao Y, Amorrortu R, Fuzzell L, Vadaparampil S, Rollison D
Cancer Med
. 2023 Apr;
12(12):13687-13700.
PMID: 37114585
Background: National Cancer Institute cancer centers (NCICCs) provide specialized cancer care including precision oncology and clinical treatment trials. While these centers can offer novel therapeutic options, less is known about...